OA06.05 Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies
Anne‐Marie C. Dingemans(Erasmus MC Cancer Institute), Thierry Berghmans(Institut Jules Bordet), Mariana Brandão(Institut Jules Bordet), Corinne Faivre‐Finn(University of Manchester), Koen J. Hartemink(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Antonin Lévy(Inserm), Elena Prisciandaro(Universitair Ziekenhuis Leuven), Egbert F. Smit(Dutch Cancer Society), Andrea Riccardo Filippi(University of Turin), Roberta De Angelis(Istituto Superiore di Sanità), Matthias Gückenberger(University Hospital of Zurich), Jules L. Derks(Maastricht University Medical Centre), Ilias Houda(Amsterdam University Medical Centers), David Sánchez-Lorente(Hospital Clínic de Barcelona), John Edwards(Sheffield Teaching Hospitals NHS Foundation Trust), Sanjay Popat(Royal Marsden NHS Foundation Trust), K. Stathopoulos(Institut Jules Bordet), Jordi Remón(Vall d'Hebron Hospital Universitari), Eleni Xenophontos(University of Cyprus), Alessio Vincenzo Mariolo(Institute Mutualiste Montsouris), Idris Bahce(Amsterdam Neuroscience), I. Opitz(Stadtspital Waid), Torsten Blum(MSB Medical School Berlin), Alessandro Brunelli(St James's University Hospital), Noemı́ Reguart(Hospital Clínic de Barcelona), Juan Trujillo(University of Alicante), Lizza Hendriks(Maastricht University), Paul Hofman(Inserm), Chris Dickhoff(Amsterdam Neuroscience)
Cited by 25
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k